Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
New Strong Buy Stocks for January 17th
07:26am, Friday, 17'th Jan 2025
RIGL, PFIS, PBPB, ICL and KMX have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2025.
Rigel (RIGL) Upgraded to Buy: Here's Why
01:00pm, Wednesday, 15'th Jan 2025
Rigel (RIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rigel Provides Business Update and 2025 Outlook
08:05am, Monday, 13'th Jan 2025
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO®
Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top Picks
10:20am, Thursday, 09'th Jan 2025
We have picked five small-cap stocks that have strong growth potential for 2025. These are: TZOO, EVER, LIND, RIGL, GHM.
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
08:05am, Thursday, 09'th Jan 2025
SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today anno
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:05am, Wednesday, 08'th Jan 2025
SOUTH SAN FRANCISCO, Calif. , Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today anno
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05am, Friday, 03'rd Jan 2025
SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. I
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents
08:30am, Monday, 30'th Dec 2024
Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three appro
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
08:50am, Monday, 23'rd Dec 2024
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses occurred in 40% of evaluable TD patients r
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
08:05am, Monday, 02'nd Dec 2024
SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today anno
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
10:56am, Tuesday, 19'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive
5 Relative Price Strength Options Available for Investors
04:01pm, Monday, 18'th Nov 2024
RIGL, SYF, SKYW, ALNT and RSI are five stocks with explosive relative price strength.
Rigel to Present at the Jefferies London Healthcare Conference
08:05am, Tuesday, 12'th Nov 2024
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ann
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
10:25pm, Thursday, 07'th Nov 2024
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
